A citation-based method for searching scientific literature

Mark M Awad, Geoffrey R Oxnard, David M Jackman, Daniel O Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C Heng, Suzanne E Dahlberg, Pasi A Jänne, Suman Verma, James Christensen, Peter S Hammerman, Lynette M Sholl. J Clin Oncol 2016
Times Cited: 313



Magda Bahcall, Mark M Awad, Lynette M Sholl, Frederick H Wilson, Man Xu, Stephen Wang, Sangeetha Palakurthi, Jihyun Choi, Elena V Ivanova, Giulia C Leonardi, Bryan C Ulrich, Cloud P Paweletz, Paul T Kirschmeier, Masayuki Watanabe, Hideo Baba, Mizuki Nishino, Rebecca J Nagy, Richard B Lanman, Marzia Capelletti, Emily S Chambers, Amanda J Redig, Paul A VanderLaan, Daniel B Costa, Yu Imamura, Pasi A Jänne. Clin Cancer Res 2018
Times Cited: 35




List of shared articles



Times cited

A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations.
Mariacarmela Santarpia, Marco Massafra, Vittorio Gebbia, Antonio D'Aquino, Claudia Garipoli, Giuseppe Altavilla, Rafael Rosell. Transl Lung Cancer Res 2021
0

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.
Matthew Lee, Prantesh Jain, Feng Wang, Patrick C Ma, Alain Borczuk, Balazs Halmos. Expert Opin Ther Targets 2021
0

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges.
Toshio Fujino, Kenichi Suda, Tetsuya Mitsudomi. Lung Cancer (Auckl) 2021
0

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Leylah M Drusbosky, Richa Dawar, Estelamari Rodriguez, Chukwuemeka V Ikpeazu. J Hematol Oncol 2021
0

Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Julia K Rotow, Philippe Gui, Wei Wu, Victoria M Raymond, Richard B Lanman, Frederic J Kaye, Nir Peled, Ferran Fece de la Cruz, Brandon Nadres, Ryan B Corcoran,[...]. Clin Cancer Res 2020
26


Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Gonzalo Recondo, Magda Bahcall, Liam F Spurr, Jianwei Che, Biagio Ricciuti, Giulia C Leonardi, Ying-Chun Lo, Yvonne Y Li, Giuseppe Lamberti, Tom Nguyen,[...]. Clin Cancer Res 2020
42

Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations.
Philippe Jamme, Marie Fernandes, Marie-Christine Copin, Clotilde Descarpentries, Fabienne Escande, Angela Morabito, Valérie Grégoire, Matthieu Jamme, Simon Baldacci, David Tulasne,[...]. J Thorac Oncol 2020
24

Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
Caiwen Huang, Qihua Zou, Hui Liu, Bo Qiu, Qiwen Li, Yongbin Lin, Ying Liang. Curr Treat Options Oncol 2020
10

The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
Ravi Salgia, Martin Sattler, Juergen Scheele, Christopher Stroh, Enriqueta Felip. Cancer Treat Rev 2020
20

Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping.
Joon Young Hur, Bo Mi Ku, Joon Ho Shim, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. In Vivo 2020
3

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B Cortot, Marina C Garassino, Julien Mazieres, Santiago Viteri, Helene Senellart, Jan Van Meerbeeck,[...]. N Engl J Med 2020
115